A Randomised, double-blind placebo controlled study of subcutaneous ketamine in the management of cancer pai

Phase 3

Completed

• Conditions: Pain from cancer or cancer treatment; Cancer - Other cancer types

• Registration Number: ACTRN12607000501448
• Lead Sponsor: Flinders University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2007-09-28
• Study Completion: 2011-02-07
• Last Update Posted: 3 April 2023

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

•age >18 years
•pain related to cancer or its treatment
•moderate to severe pain
•patients with primarily nociceptive pain (Leeds Assessment of Neuropathic Symptoms and Signs score <12), or patients with predominantly neuropathic pain (Leeds Assessment of Neuropathic Symptoms and Signs score >12) treated appropriately
•stable backgound opioid dose
•stable co-analgesics during the study period
•patient is able to give fully informed written consent

Exclusion Criteria

Previous ketamine use Unstable pain, or undergoing active treatment to reduce pain (surgery, chemotherapy, radiotherapy) Medical history places patient at risk of known adverse reactions Pregnacny/ lactation Previous recreaional drug history Recent Monoamine oxidase inhibitors (non-reversible monoamine oxidase inhibitors are excluded for 4 weeks, reversible monoamine oxidase inhibitors are excluded for 2 days).

Study & Design

• Study Type: Interventional
• Study Design: Not specified